DiagnoCure Inc. Stock Toronto S.E.

CUR

CA2519121016

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-.--%	-

02-09	Curaleaf Announces US$500 Million Senior Notes Offering	MT
16-03-14	DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	CI

9342-8530 Quebec Inc is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling, or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

02-09	Curaleaf Announces US$500 Million Senior Notes Offering	MT
16-03-14	DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	CI
16-03-11	DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2016	CI
16-02-16	Gen-Probe Incorporated completed the acquisition of assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc..	CI
16-01-21	DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended October 31, 2015; Reports Impairment of Intangible Asset for the Fourth Quarter Ended October 31, 2015	CI
15-12-22	Gen-Probe Incorporated entered into an asset purchase agreement to acquire all assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc. for CAD 6.5 million.	CI
15-09-11	DiagnoCure Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2015	CI
15-06-22	DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2015	CI
15-06-12	DiagnoCure, Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2015	CI
15-06-12	DiagnoCure Inc. Announces Board Changes	CI
15-03-06	DiagnoCure, Inc. Reports Consolidated Financial Results for the First Quarter Ended January 31, 2015	CI
15-01-23	DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Fiscal Year Ended October 31, 2014	CI
14-09-11	DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014	CI

Manager	Title	Age	Since
Yves Fradet PSD	President	75	-
Danielle Allard SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Louise Proulx IND	Independent Dir/Board Member	75	2006-03-15
Vincent R. Zurawski BRD	Director/Board Member	79	2003-04-15
Jacques Simoneau CHM	Chairman	68	2015-06-11

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAGNOCURE INC.	-.--%	-.--%	-	-	43
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+1.96%	+5.82%	+79.92%	+120.30%	27.3B
Weighted average by Cap.	+2.07%	+6.53%	+90.75%	+137.74%

DiagnoCure Inc. Stock Toronto S.E.

Stocks

CUR

CA2519121016

Biotechnology & Medical Research

Latest news : DiagnoCure Inc.

Managers and Directors: DiagnoCure Inc.

Other Biotechnology & Medical Research

Company Profile